clarithromycine for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. hydroxychloroquine plus macrolides
vs. azithromycin plus hydroxychloroquine
vs. control
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

Rashad (CLARI vs SoC), 2021

clarithromycine (n=99) vs. standard of care (n=99)

randomized controlled trial

Studied treatment

clarithromycin
500mg /12 h for 7 days

Control treatment

standard of care

3 arms azithromycin, clarithromycin or standard of care

Patients

COVID-19 mild to moderate

Method

open-label

1 centre, Egypt

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open